Abstract
Lymphotactin (Ltn) is the sole member of C chemokines which attracts T cells and NK cells specially. Ltn gene was transferred in vivo to improve the antitumor efficacy of cytosine deaminase (CD) gene therapy. Upregulation of CD80 and CD54 on murine CT26 colon carcinoma cells was observed after combined transfection with adenovirus encoding CD (AdCD) and adenovirus encoding murine Ltn (AdLtn) followed by administration of 5-fluorocytosine (5FC) in vitro. AdCD/5FC treatment also increased the expression of CD95 and induced obvious apoptosis of CT26 cells. After combined treatment with AdLtn and AdCD/5FC, the pre-established murine model with subcutaneous CT26 colon carcinoma exhibited most significant tumor growth inhibition, and four of eight tumor-bearing mice were tumor free, while tumors in other mice grew more progressively. Examination of lymphocyte infiltration and cytokine gene expression in tumor tissue revealed that tumors from AdLtn/AdCD/5FC-or AdLtn-treated mice were heavily infiltrated with CD4+, CD8+ T cells and NK cells, and IL-2 and IFN-γ mRNA expression were present in parallel with T cell and NK cell infiltration. Splenic NK and CTL activities increased significantly after the combination therapy. In vivo depletion analysis showed that NK cells, CD4+ T cells and CD8+T cells participated in the antitumor effect of the host with CD8+T cells being the main T cell subset responsible for the enhanced antitumor immune response. These findings suggested that increased immunogenicity and induction of apoptosis of the tumor cells, and efficient induction of local and systemic antitumor immunity of the host might contribute to the enhanced antitumor effects of the combined Ltn and CD suicide therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mullen CA . Metabolic suicide genes in gene therapy Pharm Ther 1994 63: 199–207
Tiberghien P . Use of suicide genes in gene therapy J Leuk Biol 1994 56: 203–209
Deonarain MP, Spooner RA, Epenetos AA . Genetic delivery of enzymes for cancer therapy Gene Therapy 1995 2: 235–244
Dilber MS et al. Suicide gene therapy for plasma cell tumors Blood 1996 88: 2192–2200
Crystal RG et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine Hum Gene Ther 1997 8: 985–1001
Dong Y et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine Hum Gene Ther 1996 7: 713–720
Li Z et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase Cancer Gene Ther 1997 4: 113–117
Topf N, Worgall S, Hackett NR, Crystal RG . Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma Gene Therapy 1998 5: 507–513
Wolff G et al. Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation Hum Gene Ther 1998 9: 2277–2284
Pederson LC et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo Cancer Res 1997 57: 4325–4332
Freeman SM, Ramesh R, Marrogi AJ . Immune system in suicide-gene therapy Lancet 1997 349: 2–3
Cao X et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor tesponse in tumor-bearing mice Gene Therapy 1998 5: 1130–1136
Cao X et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity J Immunol 1998 161: 6238–6244
Ju DW, Wang B, Cao X . Combined suicide gene and interleukin 2 gene therapy for the treatment of established tumor and induction of antitumor immunity in leukemia-bearing mice J Cancer Res Clin Oncol 1998 124: 683–689
Ju DW, Cao X, Acres B . Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a murine melanoma model Cancer Gene Ther 1997 4: 139–144
Cheon J et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model Cancer Gene Ther 1997 4: 359–365
Fioretti F et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor J Immunol 1998 161: 342–346
Bottazzi B et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma J Immunol 1992 148: 1280–1285
Nakashima E et al. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice Pharm Res 1996 13: 1896–1901
Kelner GS et al. Lymphotactin: a cytokine that represents a new class of chemokine Science 1994 226: 1395–1399
Hedrick JA et al. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo J Immunol 1997 158: 1533–1540
Hedrick JA, Zlotnik A . Lymphotactin Clin Immunol Immunopathol 1998 87: 218–222
Hedrick JA, Zlotnik A . Lymphotactin: a new class of chemokine Meth Enzymol 1997 287: 206–215
Giancarlo B et al. Migratory response of human natural killer cells to lymphotactin Eur J Immunol 1996 26: 3238–4241
Aghi M et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies J Natl Cancer Inst 1998 90: 370–380
Hanna NN et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts Cancer Res 1997 57: 4205–4209
Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, doule suicide gene, and radiotherapy Hum Gene Ther 1998 9: 1323–1333
Rogulski KR, Kim JH, Kim SH, Freytag SO . Glioma cells transduced with an Escherichia coli CD/HSV 1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity Hum Gene Ther 1997 8: 73–85
Kwong YL et al. Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer Chest 1997 112: 1332–1337
Santodonato L et al. Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir Gene Therapy 1996 7: 1–10
Nanni P et al. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-γ and cytosine deaminase genes cures lung metastases by parental cells Hum Gene Ther 1998 9: 217–224
Yoon SJ et al. Synergistic antitumor effects with co-expression of GM-CSF and IFN-γ in murine tumors Int J Cancer 1998 77: 907–912
Benedetti S et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene Hum Gene Ther 1997 8: 1345–1353
Mule JJ et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations Hum Gene Ther 1996 7: 1545–1553
Nakashima E et al. Synergistic antitumor interaction of human monocyte chemotactant protein-1 gene transfer and modulator for tumor-infiltrating macrophages Pharm Res 1998 15: 685–689
Wang J et al. Lymphotactin: a key regulator of lymphocyte trafficking during acute graft rejection Immunology 1998 95: 56–61
Dilloo D et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity Nature Med 1996 2: 1090–1095
Bi W et al. An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice Cancer Gene Ther 1997 4: 246–252
Denning C, Pitts JD . Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes Hum Gene Ther 1997 8: 1825–1835
Chong H et al. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte–macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity Gene Therapy 1998 5: 223–232
Uzendoski K et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses Hum Gene Ther 1997 8: 851–860
Ramesh R et al. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene Cancer Gene Ther 1996 3: 373–384
Hall SJ, Sanford MA, Atkinson G, Chen SH . Induction of potent antitumor natural killer activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an mouse model of prostate cancer Cancer Res 1998 58: 3221–3225
Kanai F et al. In vivo gene therapy for alpha fetoprotein producing hepatocellular carcinoma by adenovirus mediated transfer of cytosine deaminase gene Cancer Res 1997 57: 461–465
Cavallo F et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response of nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene J Immunol 1992 149: 3627–3635
Consalvo M et al. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory J Immunol 1995 154: 5302–5312
Toda M, Martuza RL, Kojima H, Rabkin SD . In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity J Immunol 1998 160: 4457–4464
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No. 39600181) and National High Biotechnology Project of China (Z20–01–03).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ju, D., Tao, Q., Cheng, D. et al. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Ther 7, 329–338 (2000). https://doi.org/10.1038/sj.gt.3301082
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301082
Keywords
This article is cited by
-
Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism
Cancer Immunology, Immunotherapy (2011)
-
Effects of Livin gene RNA interference on apoptosis of cervical cancer Hela cells and enhanced sensitivity to cisplatin
Journal of Huazhong University of Science and Technology [Medical Sciences] (2009)
-
Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model
Cancer Gene Therapy (2007)
-
Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors
Cell Research (2006)
-
Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity
Gene Therapy (2002)